The promise of siRNAs for the treatment of influenza.
Current WHO reports on the Asian avian influenza virus outbreaks are poignant reminders of the potential for the emergence of highly virulent strains of influenza A virus (IAV) and the fact that it remains a scourge on human health. As IAV drifts and shifts its genetic and antigenic composition, it presents an ever-changing challenge for vaccines and antiviral medications. Short-interfering RNAs (siRNAs) are the latest class of potential antiviral therapeutics to be developed. Recent reports using siRNAs in mice suggest that they hold great promise for the prevention and treatment of IAV infections.
Bennink
Jack R
JR
National Institutes of Health, National Institute of Allergy and Infectious Diseases, Laboratory of Viral Diseases, 4 Center Drive, Bethesda, MD 20892, USA. jbennink@nih.gov
Palmore
Tara N
TN
D000818:Animals; D000998:Antiviral Agents / Q000627:therapeutic use*; D006801:Humans; D009980:Influenza A virus / Q000235:genetics; D007251:Influenza, Human / Q000188:drug therapy*; D051379:Mice; D034622:RNA Interference / Q000502:physiology; D034741:RNA, Small Interfering / Q000627:therapeutic use*
D000998:Antiviral Agents; D034741:RNA, Small Interfering